Skip to main content

Table 1 Participant & family demographic and clinical characteristics at recruitment

From: FAB: First UK feasibility trial of a future randomised controlled trial of Family focused treatment for Adolescents with Bipolar disorder

 

Immediate arm, n = 14

Delayed arm, n = 13

Total, n = 27

Age in years: mean (sd)

16.2 (1.3)

16.1 (1.5)

16.1 (1.4)

Index of Multiple Deprivation: mean (sd)

23.4 (14.8)

23.2 (11.1)

23.3 (12.9)

CGAS rating: mean (sd)

 Current (last 2 weeks)

84 (7)

81.4 (5.2)

82.7 (6.3)

 Most severe past episode

25.1 (5)

22.4 (8.1)

23.8 (6.8)

 Highest in prior year

81 (7)

81.5 (5)

81.2 (7)

Gender: n (%)

 Female

13 (92.9)

10 (76.9)

23 (85.2)

Ethnicity: n (%)

 White British

13 (92.9)

12 (92.3)

25 (92.6)

 White other

0 (0)

1 (7.7)

1 (3.7)

 Mixed

1 (7.1)

0 (0)

1 (3.7)

Type of bipolar disorder: n (%)

 Bipolar I

8 (57.1)

7 (53.8)

15 (55.6)

 Bipolar II

6 (42.9)

5 (38.5)

11 (40.7)

 Bipolar NOS

0 (0)

1 (7.7)

1 (3.7)

Comorbid disorders

 GAD

0 (0)

2 (15.4)

2 (7.4)

 ASD

2 (14.3)

2 (15.4)

4 (14.8)

 ADHD

1 (7.1)

0 (0)

1 (3.7)

 ASD + ADHD

1 (7.1)

0 (0)

1 (3.7)

 Substance abuse or dependence disorder (past 3 months)

0 (0)

0 (0)

0 (0)

Mood episodes

 Age of diagnosis of BD in years mean (sd)

12.8 (1.6)

12.9 (1.3)

12.8 (1.4)

Hypomania

 Number of participants n (%)

8 (57.1)

8 (61.5)

16 (59.3)

 Number of episodes mean (sd)

3 (1.1)

2.9 (2)

3 (1)

 Lifetime duration in weeks mean (sd)

7.8 (4.4)

8.6 (4.5)

8.1 (4.3)

 Admissions to hospital

0 (0)

0 (0)

0 (0)

Mania

 Number of participants n (%)

8 (57.1)

7 (53.8)

15 (55.6)

 Number of episodes mean (sd)

2.9 (0.8)

2.7 (0.8)

2.8 (0.8)

 Lifetime duration in weeks mean (sd)

13.4 (5.2)

14 (5.3)

13.7 (5.1)

 Number of participants experiencing psychotic episodes n (%)

5 (35.7)

4 (30.1)

9 (33.3)

 Admissions to hospital n (%)

4 (30.1)

3 (23.1)

7 (25.9)

Depression

 Number of participants n (%)

14 (100)

13 (100)

27 (100)

 Number of episodes mean (sd)

4.2 (1.1)

4.2 (1.1)

4.2 (1.1)

 Lifetime duration in weeks mean (sd)

37.2 (16.9)

35.9 (16.2)

36.6 (16.5)

 Number of participants experiencing psychotic episodes n (%)

10 (71.4)

9 (69.2)

19 (70.4)

 Admissions to hospital n (%)

7 (50)

6 (46.2)

13 (48.1)

Medication treatments at trial entry

 Mood stabilizer

5 (35.7)

5 (38.5)

10 (37)

 Antipsychotic

8 (57.1)

10 (76.9)

18 (66.7)

 Other

1 (7.1)

0 (0)

1 (3.7)

 None

4 (28.6)

0 (0)

4 (14.8)

Family medical history (first degree relatives)

 Bipolar disorder

5 (35.7)

4 (30.8)

9 (33.3)

 Depression

4 (28.6)

10 (76.9)

14 (51.9)

 Anxiety

2 (14.3)

1 (7.7)

3 (11.1)

 ADHD

2 (14.3)

3 (23.1)

5 (18.5)

 ASD

2 (14.3)

2 (15.4)

4 (14.8)

 Physical illness

1 (7.1)

0 (0)

1 (3.7)

 Other

2 (14.3)

3 (23.1)

5 (18.5)

  1. CGAS Children’s Global Assessment Scale, NOS not otherwise specified, GAD generalised anxiety disorder, ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder